Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc. and RXi Pharmaceuticals Corporation announced that they have obtained positive early research data from their collaboration to explore the use of RXi's RNAi technology to develop proprietary vaccine formulations for active immunotherapy.

Initial results from the collaboration demonstrated success in using RXi's proprietary self-delivering rxRNA(TM) compounds to silence genes up to 80% in hemopoietic cells.  The ability to knock down expression of certain genes in isolated hemopoietic-derived cancer cells (ex vivo) has the potential to convert them into specific immune-stimulants and opens the possibility for development of a new class of anticancer therapeutic vaccines.  RXi's sd-rxRNA compounds may be particularly suitable for this use, since they are able to cross cell membranes without the assistance of any delivery agent.

Source:

Generex Biotechnology Corporation